HIV-1 and TB co-infection skew the SARS-CoV-2 T cell response
SARS-CoV-2-specific CD4 T cell attributes, rather than magnitude, associate with disease severity, with severe disease being characterized by poor polyfunctional potential, reduced proliferation capacity and enhanced HLA-DR expression.
Image of scientist holding up a Petri dish
Supporting Excellence
The Wellcome Centre for Infectious Diseases Research in Africa fosters investigator-led approaches via the overarching scientific objective of combatting infection, especially HIV-1 and tuberculosis, through clinical and laboratory research.
Macrophages infected with M. tuberculosis; image by Dr Suraj Parihar
Basic Science
Our Basic Science Platform provides the laboratory infrastructure and technical support to ensure the safe handling of infectious material.
Subgraph of the ANIMA network for dataset HIVsetB
Biomedical Data Integration
We work with multidimensional clinical and scientific data at the molecular, cellular, clinical and population levels.
Image of a researcher and study participant reading an informed consent document
Clinical Research
CIDRI-Africa supports clinical studies in the community at our facility at Site B in Khayelitsha.


Tuesday, 19 October 2021
Person wearing gloves and labelling tubes in a laboratory
T cells face off against variants to boost COVID-19 immunity

With the fight against COVID-19 beset with concerns around the efficacy of vaccines in the face of a mutating virus, University of Cape Town virologists have shown that the body’s T cells maintain 85% of their capacity to detect variants, continuing to mount a substantial defence to prevent severe illness, hospitalisation and death.

Publication Date:
Thu, 12 Aug 2021 - 12:00
An icon of a medicine capsule on a two-tone blue background
HIV infection may be driving drug resistance in tuberculosis

Results published today in The Lancet Microbe detail analysis of 10 years’ health data, showing a relationship between HIV infection and acquisition of rifampicin resistance by tuberculosis. Rifampicin is an important first-line anti-tuberculosis medication.

Publication Date:
Thu, 12 Aug 2021 - 09:00
The storm after the calm: the alpha, beta and gamma variants of SARS-CoV-2 are converging on similar adaptive endpoints

Ongoing adaptive evolutionary convergence of the alpha, beta and gamma variants could lead to additional variants displaying any combination of increased transmissibility, altered virulence and/or increased capacity to escape population immunity.

Publication Date:
Mon, 02 Aug 2021 - 09:15
People with diabetes at risk of severe COVID-19, study confirms

A recent study from the University of Cape Town (UCT) confirmed that people living with diabetes (PLWD) are at an increased risk of severe COVID‑19 (hospitalisation and mortality). The findings were published in the journal Diabetes Research and Clinical Practice.

Publication Date:
Tue, 20 Jul 2021 - 09:00